EWTX is a cash-rich cardiovascular biotech challenger whose non-LVEF-degrading EDG-7500 could unlock underserved HCM markets, though Phase 3 execution remains decisive.
Overview
Edgewise Therapeutics (EWTX) is a pre-revenue clinical-stage biotechnology company that has pivoted from muscular dystrophy to a pure-play cardiovascular platform after selling its entire muscular dystrophy business, including sevasemten, to Servier for up to $2.65 billion. The transaction delivered $1.55 billion upfront, taking pro-forma cash to approximately $2.05 billion and materially reducing dilution risk. **The lead asset, EDG-7500, could disrupt cardiac myosin inhibitors by improving HCM hemodynamics and diastolic function without meaningful LVEF impairment or mandated monitoring.** In Phase 2 CIRRUS-HCM Part D, 74% of obstructive and 88% of non-obstructive patients achieved at least 50% NT-proBNP reduction or normalization, while no patient’s LVEF fell below 50%. The pipeline also includes EDG-15400 for HFpEF and preclinical EDG-003. Q1 2026 revenue was zero, with a $49.013 million net loss, but the $2.05 billion cash balance is expected to fund EDG-7500 through potential FDA approval. Near-term catalysts are EDG-7500 Phase 3 initiation in Q4 2026, EDG-15400 Phase 2 initiation in 2H 2026, and up to $1.1 billion of Servier milestones. The report’s probability-weighted five-year price target is $67.81 versus $45.41 currently.